News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
EMA and FDA Collaborate on Framework for AI Use in Drug Development
2
PharmTech Weekly News Roundup – Week of January 12, 2026
3
The Impact of Patient-Centric Formulations on Service Providers
4
Analytical Strategies for Aseptic Processing
5